Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza A H1N1 (H275Y) oseltamivir-resistant and wild-type viruses

Journal of Medical Virology

Volumn 82, Issue 8, 2010, Pages 1295-1298

  Ngai, Karry L K ^a   Lam, Wai Yip ^a   Lee, Nelson ^a   Leung, Ting Fan ^a   Hui, David S C ^a   Chan, Paul K S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Allele specific; H274Y; H275Y; Neuraminidase inhibitor; Rapid diagnosis; Resistance; Screening

Indexed keywords

OSELTAMIVIR; SIALIDASE; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; VIRUS PROTEIN; VIRUS RNA;

ALLELE; ARTICLE; GENE SEQUENCE; HUMAN; HUMAN CELL CULTURE; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; NASOPHARYNGEAL ASPIRATION; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; VIRUS MUTANT; VIRUS TITRATION; WILD TYPE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CLASSIFICATION; DNA SEQUENCE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; INFLUENZA; ISOLATION AND PURIFICATION; MASS SCREENING; MOLECULAR GENETICS; NASOPHARYNX; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MASS SCREENING; MOLECULAR SEQUENCE DATA; NASOPHARYNX; NEURAMINIDASE; OSELTAMIVIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS; VIROLOGY;

EID: 77956594163     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21783     Document Type: Article

References (14)

1. Baz M, Abed Y, Boivin G. 2007. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 74:159-162. (Pubitemid 46436166)
2. Bolotin S, Robertson AV, Eshaghi A, De Lima C, Lombos E, Chong-King E, Burton L, Mazzulli T, Drews SJ. 2009. Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates. J Virol Methods 158:190-194.
3. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel J, Martin SR, Hay AJ, Gamblin SJ. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258-1262.
4. Colmon PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44. (Pubitemid 13125071)
5. Goodman C, Mukherjee D, Faulkner E. 2006. How effective would antiviral vaccination and antiviral drug prevention and treatment strategies be for reducing the impact of the next influenza pandemic? WHO Regional Office for European, Copenhagen. Health Evidence Network Report. http://www.euro.who.int/ Document/E88034.pdf [accessed on November 2, 2009].
6. Guo L, Garten RJ, Foust AS, Sessions WM, Okomo-Adhiambo M, Gubareva LV, Klimov A, Xu X. 2009. Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Res 82:29-33.
7. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55:307-317.
8. Kwok S, Kellogg DE, Mckinney N, Spasic D, Goda L, Levenson C, Sninsky JJ. 1990. Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency virus type 1 model studies. Nucleic Acids Res 18:999-1005.
9. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC. 2008. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eur Surveill 13:1-3.
10. Liu CM, Driebe EM, Schupp J, Kelley E, Nguyen JT, McSharry JJ, Weng Q, Engelthaler DM, Keim P. 2010. Rapid quantification of single-nucleotide mutations inmixed influenza A viral populations using allele-specific mixture analysis. J Virol Methods 163:109-115.
11. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, Schweiger B, Opp M, Paget J, van de Kassteele J, Hay A, Zambon N. 2009. Oseltamivir-resistance influenza viruses A/H1N1, Europe, 2007-08 season. Emerg Infect Dis 15:552-560.
12. Varghese JN, Mckimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332.
13. WHO. 2009a. Influenza A(H1N1) virus resistance to oseltamivir, 2008-2009 influenza season, northern hemisphere. http://www.who.int/csr/disease/influenza/ 2008-9nhemisummaryreport/en/index.html [accessed on November 2, 2009].
14. WHO. 2009b. Pandemic (H1N1) 2009: Antiviral drug resistance. http://www.who.int/csr/disease/swineflu/frequently-asked-questions/antivirals/ resistance/en/print.html [accessed on January 27, 2010].